

Management of Apnoea on the Neonatal Unit – Full Clinical guideline – Burton only

Reference no.: CG/PAEDS/4027/22

1. Introduction

Apnoea is defined as cessation of breathing for more than 20 seconds. It can occur in newborn infants due to a number of conditions. It is frequently associated with bradycardia and hypoxemia (fall in oxygen saturation).

In infants of any gestational age, frequent episodes of apnoea may indicate an underlying illness such as an infection. Infants must be appropriately assessed to ensure that any underlying pathology is investigated and treated, if required.

Apnoea of prematurity is the occurrence of frequent apnoeic episodes, often with bradycardia and desaturations, in infants born at <34 weeks gestational age. It is almost universal among extremely premature infants. It is presumed to be caused by the immaturity of the central respiratory control systems.

2. Aim and Purpose

- Diagnosis, investigations, and management of apnoea in newborn infants
- Use of caffeine for management of apnoea of prematurity
- Guidance for heart rate and oxygen saturation monitoring for apnoea, bradycardia, and oxygen desaturations

3. Definitions, Keywords

Apnoea: cessation in breathing lasting for more than 20 seconds

Bradycardia: fall in heart rate to less than 90 beats per minute

Desaturation: fall in oxygen saturation level below the target range of 91-95% or as appropriate for corrected gestational age.

4. Main body of Guidelines

Infants who have frequent episodes of apnoea, especially when these episodes are associated with bradycardia and/or desaturations, and/or need physical stimulation or positive pressure ventilation to recover, must be clinically assessed to consider conditions such as:

- An inter-current respiratory illness such as lung infection or atelectasis
- Sepsis
- Necrotising enterocolitis
- Metabolic disturbances including hypoglycaemia
- Underlying neurological disorder such as causes of central hypotonia, or loss of respiratory drive

- Neonatal encephalopathy (HIE, meningitis, intracranial haemorrhage, seizures)
- Anaemia
- Gastro-oesophageal reflux disease

In the absence of suspicion of such pathological conditions, preterm infants who have apnoea should be considered to have apnoea of prematurity.

Treatment of apnoea of prematurity

Caffeine is the most commonly used treatment for apnoea of prematurity. It reduces the frequency of apnoea, intermittent hypoxemia, and risk of chronic lung disease.

Caffeine therapy in preterm infants may improve long term outcomes: infants who received caffeine in a large randomised controlled trial (the Caffeine for Prematurity (CAP) trial) had higher rates of survival without neurodisability at 18-21 months of age (1). Although there was no difference between the groups as 5 years of age (2), follow up at 11 years of age found significantly reduced motor impairment among those who had been treated with caffeine (3).

Caffeine also reduced the risk of extubation failure in very preterm infants (4).

Caffeine is easy to administer, cost effective, and well tolerated by infants.

Potential adverse effects of caffeine include tachycardia, increase urinary sodium loss, glucose intolerance, and jitteriness. However, in practice, these are very rare at the usual doses of caffeine used in newborn infants.

Caffeine, especially at high doses, may worsen gastro-oesophageal reflux disease.

Indication for caffeine therapy

- Infants born at < 32 weeks gestational age
- Infants born at <34 weeks gestational age requiring mechanical ventilation (prior to planned extubation)
- Any infant suspected to have apnoea of prematurity

Treatment regimen

Route of administration

Oral or intravenous (IV); oral route is preferred in infant is on enteral feeds

Loading dose

20 mg/kg caffeine citrate

Maintenance dose

5 mg/kg caffeine citrate once daily starting 24 hours after the loading dose. Can be increased to 10 mg/kg once daily if required.

Preparation and administration (Please Note this is different from Derby site)

Caffeine citrate 20mg/ml in 1ml ampoules – suitable for IV & oral administration

- IV infusion – may be diluted with sodium chloride 0.9% or glucose 5%
- Give Loading dose IV infusion over 30mins
- Give Maintenance dose IV infusion over 10mins
- Oral – use the injection orally – use filter straw

Compatibilities: The injection is compatible with sodium chloride 0.9% and glucose 5%

Monitoring caffeine levels

Only measure plasma concentrations of caffeine if inadequate clinical response, desired range 10-20mg/l (50-100 micromol/l) (see British National Formulary –children for further guidance)

Stopping caffeine

Caffeine has a long half-life and can be abruptly stopped. Caffeine can be stopped in infants who are over 34 weeks corrected gestational age and are no longer having apnoea.

Heart rate and oxygen saturation monitoring

Infants having apnoea, bradycardia, or desaturations, and those of caffeine therapy should be monitored with continuous heart rate and oxygen saturation monitoring.

Continuous heart rate and oxygen saturation monitoring can be stopped when the infants remain free of apnoeic episodes two days after stopping the caffeine treatment.

Apnoea monitors are no longer available in the neonatal unit and are not for use routinely. Infants who are not on continuous monitoring should have respiratory rate, colour, tone, and temperature recorded with every feed (3-4 hourly). Special care rooms where an infant is not monitored **MUST NOT** be left unattended. A member of staff should always be present in the room.

Management of apnoea unresponsive to caffeine treatment

- Consider other causes of frequent/recurrent apnoea
- Use nasal CPAP to support breathing, may need further respiratory support i.e. mechanical ventilation

5. References (including any links to NICE Guidance etc.)

1. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, et al. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354(20):2112-21
2. Schmidt B, Anderson PJ, Doyle LW, Dewey D, Grunau RE, Asztalos EV, et al. Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. JAMA. 2012;307(3):275-82

Reference no.:

3. Schmidt B, Roberts RS, Anderson PJ, Asztalos EV, Costantini L, Davis PG, et al. Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial. *JAMA Pediatr.* 2017;171(6):564-72
4. Henderson-Smart DJ, Davis PG. Prophylactic methylxanthines for endotracheal extubation in preterm infants. *Cochrane Database Syst Rev.* 2010(12):CD000139

Documentation Controls

Reference Number CG – PAEDS/4027/22	Version: V001		Status Final		
Version / Amendment History	Version	Date	Author	Reason	
				New guideline required	
Intended Recipients: Neonatal nurses, Paediatric doctors					
Training and Dissemination: Cascaded electronically through to intended recipients via email. Published on Trust guideline intranet page					
Development of Guideline: Modified for Burton site by Dominic Muogbo from Derby site guideline written by Shalini Ojha, Karen Sampson Job Title: Consultant Paediatrician					
Consultation with: Neonatal Consultants, Senior neonatal nurses, Paediatric/Neonatal Pharmacist					
Linked Documents: NA					
Keywords: Apnoea, Caffeine, prematurity					
Business Unit Sign Off			Group: Paediatric Guidelines Group Date: 08/06/2022		
Divisional Sign Off			Group: Women and Children's Clinical Governance Group Date: 28/06/2022		
Date of Upload			July 2022		
Review Date			June 2025		
Contact for Review			Dominic Muogbo		

